https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Economic evaluation of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) for stroke prevention in patients with atrial fibrillation: a systematic review and meta-analysis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48555 Wed 22 Mar 2023 09:17:49 AEDT ]]> Comparative efficacy and safety of pharmacologic interventions to prevent mother-to-child transmission of hepatitis B virus: a systematic review and network meta-analysis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51837 Wed 20 Sep 2023 16:11:23 AEST ]]> Comparative cardiovascular benefits of individual SGLT2 inhibitors in type 2 diabetes and heart failure: a systematic review and network meta-analysis of randomized controlled trials https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54369 Tue 20 Feb 2024 19:56:52 AEDT ]]> Meta-analysis of economic evaluation studies: data harmonisation and methodological issues https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48929 Mon 17 Apr 2023 11:14:14 AEST ]]> Diagnostic performance of clinic and home blood pressure measurements compared with ambulatory blood pressure: a systematic review and meta-analysis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:37549 Mon 15 Feb 2021 09:16:20 AEDT ]]> Glucagon-like peptide 1 agonists for treatment of patients with type 2 diabetes who fail metformin monotherapy: systematic review and meta-analysis of economic evaluation studies https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:40026 2=0%), US$3857.34 (95% CI US$−7293.93 to US$15 008.61, I²=45.9%), US$37 577.74 (95% CI US$−649.02 to US$75 804.50, I²=92.4%) and US$14 062.42 (95% CI US$8168.69 to US$19 956.15, I²=86.4%), respectively. GLP1s were statistically significantly cost-effective compared with insulins, but not compared with DPP4i, sulfonylureas, and TZDs. Among GLP1s, liraglutide was more cost-effective compared with lixisenatide, but not compared with exenatide, with corresponding pooled INBs of US$4555.09 (95% CI US$3992.60 to US$5117.59, I²=0) and US$728.46 (95% CI US$−1436.14 to US$2893.07, I²=0), respectively. Conclusion: GLP1 agonists are a cost-effective choice compared with insulins, but not compared with DPP4i, sulfonylureas and TZDs. PROSPERO registration number: CRD42018105193.]]> Fri 15 Jul 2022 10:11:12 AEST ]]> Efficacy and safety of monoclonal antibody therapy in patients with neuromyelitis optica spectrum disorder: A systematic review and network meta-analysis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53516 Fri 01 Dec 2023 11:06:04 AEDT ]]>